National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 9) (Cth)

Case

PB 121 of 2023

National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 9)

I, Nikolai Tsyganov, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination:

Dated         30      November 2023

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments  2

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) 2

1  Name

This instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 9).

  This instrument may also be cited as PB 121 of 2023.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1 Column 2 Column 3
Provisions Commencement Date/Details
1.  The whole of this instrument 1 December 2023

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

This instrument is made under section 85B of the National Health Act 1953.

4  Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022)

  1. Schedule 1 – Omit entry for Alendronic acid with colecalciferol

Omit

Alendronic acid with colecalciferol Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol Oral Fosamax Plus 4 5.13 8.13
Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol Oral Fosamax Plus 70 mg/140 mcg 4 5.13 8.13
  1. Schedule 1 – entry for Budesonide with formoterol

Omit

Budesonide with formoterol Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses Inhalation by mouth Symbicort Turbuhaler 400/12 1 22.07 23.93
Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses Inhalation by mouth Symbicort Turbuhaler 200/6 1 22.33 26.05

Insert

Budesonide with formoterol Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses Inhalation by mouth Symbicort Turbuhaler 400/12 1 22.07 23.93
Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses Inhalation by mouth Symbicort Turbuhaler 200/6

1

22.33 26.05

Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses

Inhalation by mouth Symbicort Rapihaler 100/3 1 13.40 15.71
Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses Inhalation by mouth Symbicort Rapihaler 200/6 1 22.06 24.37
  1. Schedule 1 – entry for Cefuroxime

Omit

Cefuroxime Tablet 250 mg (as axetil) Oral Zinnat 20 5.27 9.71

Insert

Cefuroxime Tablet 250 mg (as axetil) Oral Zinnat 20 5.27 11.16
  1. Schedule 1 – entry for Donepezil

Omit

Donepezil Tablet containing donepezil hydrochloride 5 mg Oral Aricept 28 7.44 10.16
Tablet containing donepezil hydrochloride 10 mg Oral Aricept 28 7.44 14.09

Insert

Donepezil Tablet containing donepezil hydrochloride 5 mg Oral Aricept 28 7.44 15.20
Tablet containing donepezil hydrochloride 10 mg Oral Aricept 28 7.44 15.15
  1. Schedule 1 – entry for Flecainide

Omit

Flecainide Tablet containing flecainide acetate 50 mg Oral Tambocor 60 14.94 17.38
Tablet containing flecainide acetate 100 mg Oral Tambocor 60 18.52 20.97

Insert

Flecainide Tablet containing flecainide acetate 50 mg Oral Tambocor 60 14.94 21.04
Tablet containing flecainide acetate 100 mg Oral Tambocor 60 18.52 25.12
  1. Schedule 1 – entry for Fluticasone propionate with salmeterol

Omit

Fluticasone propionate with salmeterol Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) Inhalation by Mouth Seretide MDI 125/25 1 27.07 29.98
Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) Inhalation by Mouth Seretide MDI 250/25 1 36.65 39.56
Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth Seretide Accuhaler 100/50 1 28.34 32.06
Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth Seretide Accuhaler 250/50 1 27.07 29.98
Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth Seretide Accuhaler 500/50 1 36.65 39.56
Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) Inhalation by Mouth Seretide MDI 50/25 1 28.34 32.06

Insert

Fluticasone propionate with salmeterol Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) Inhalation by Mouth Seretide MDI 125/25 1 27.07 30.79
Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) Inhalation by Mouth Seretide MDI 250/25 1 36.65 40.37
Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth Seretide Accuhaler 100/50 1 28.34 32.06
Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth Seretide Accuhaler 250/50 1 27.07 30.79
Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses Inhalation by Mouth Seretide Accuhaler 500/50 1 36.65 40.37
Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC‑free formulation) Inhalation by Mouth Seretide MDI 50/25 1 28.34 32.06
  1. Schedule 1 – entry for Indapamide

Omit

Indapamide Tablet containing indapamide hemihydrate 1.5 mg (sustained release) Oral Natrilix SR 90 6.24 12.03

Insert

Indapamide Tablet containing indapamide hemihydrate 1.5 mg (sustained release) Oral Natrilix SR 90 6.24 13.42
  1. Schedule 1 – entry for Naproxen

Omit

Naproxen Tablet 1 g (sustained release) Oral Naprosyn SR1000 28 5.41 6.33
Tablet 750 mg (sustained release) Oral Naprosyn SR750 28 4.06 4.93
Tablet containing naproxen sodium 550 mg Oral Anaprox 550 50 4.55 6.11

Insert

Naproxen Tablet 1 g (sustained release) Oral Naprosyn SR1000 28 5.41 7.60
Tablet 750 mg (sustained release) Oral Naprosyn SR750 28 4.06 6.34
Tablet containing naproxen sodium 550 mg Oral Anaprox 550 50 4.55 7.26
  1. Schedule 1 – Omit entry for Ondansetron

Omit

Ondansetron Wafer 4 mg Oral Zofran Zydis 10 11.04
Wafer 8 mg Oral Zofran Zydis 4 5.35 7.63
Oral Zofran Zydis 10 15.66

Insert

Ondansetron Wafer 4 mg Oral Zofran Zydis 10 8.75 11.04
Wafer 8 mg Oral Zofran Zydis 10 5.35 15.66
  1. Schedule 1 – entry for Rosuvastatin

Omit

Rosuvastatin Tablet 5 mg (as calcium) Oral Crestor 30 2.50 5.96
Tablet 10 mg (as calcium) Oral Crestor 30 3.50 6.87
Tablet 20 mg (as calcium) Oral Crestor 30 3.55 6.89
Tablet 40 mg (as calcium) Oral Crestor 30 5.06 9.16

Insert

Rosuvastatin Tablet 5 mg (as calcium) Oral Crestor 30 2.50 7.11
Tablet 10 mg (as calcium) Oral Crestor 30 3.50 8.09
Tablet 20 mg (as calcium) Oral Crestor 30 3.55 8.15
Tablet 40 mg (as calcium) Oral Crestor 30 5.06 9.65
Actions
Download as PDF Download as Word Document


Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0